Agilent (A) Gets a Buy from Barclays
Barclays analyst Luke Sergott maintained a Buy rating on Agilent today and set a price target of $150.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Sergott is an analyst with an average return of -2.5% and a 40.51% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Charles River Labs, Agilent, and Qiagen.
In addition to Barclays, Agilent also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Diagnostics and Research in a report issued yesterday. However, on the same day, TipRanks – xAI downgraded Agilent (NYSE: A) to a Hold.
Based on Agilent’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $1.86 billion and a net profit of $434 million. In comparison, last year the company earned a revenue of $1.7 billion and had a net profit of $351 million
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of A in relation to earlier this year. Most recently, in December 2025, Rodney Gonsalves, the V.P., Corporate Controller of A sold 3,119.00 shares for a total of $483,310.03.
Read More on A:
